Get started
Author

Binhua Lv

ORCID: 0000-0002-2006-2554
Observed ORCID: 0000-0002-2006-2554
OpenAlex ID: A5037970000
EGT1442, a potent and selective SGLT2 inhibitor, attenuates blood glucose and HbA1c levels in db/db mice and prolongs the survival of stroke-prone rats
2011 · Wenbin Zhang, Ajith Welihinda, et al. · Pharmacological Research · 80
Design, Synthesis, and Biological Evaluation of Deuterated C-Aryl Glycoside as a Potent and Long-Acting Renal Sodium-Dependent Glucose Cotransporter 2 Inhibitor for the Treatment of Type 2 Diabetes
2014 · Ge Xu, Binhua Lv, et al. · Journal of Medicinal Chemistry · 65
Exploration of O-spiroketal C-arylglucosides as novel and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors
2009 · Binhua Lv, Baihua Xu, et al. · Bioorganic & Medicinal Chemistry Letters · 37
C-Aryl glucosides substituted at the 4′-position as potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes
2011 · Baihua Xu, Yan Feng, et al. · Bioorganic & Medicinal Chemistry Letters · 32
A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Ascending Dose and Food Effect Study to Evaluate the Tolerance, Pharmacokinetics of Jaktinib, a New Selective Janus Kinase Inhibitor in Healthy Chinese Volunteers
2020 · Jingrui Liu, Binhua Lv, et al. · Frontiers in Pharmacology · 28
PDF
O-Spiro C-aryl glucosides as novel sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors
2009 · Baihua Xu, Binhua Lv, et al. · Bioorganic & Medicinal Chemistry Letters · 26
ortho-Substituted C-aryl glucosides as highly potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors
2010 · Baihua Xu, Yan Feng, et al. · Bioorganic & Medicinal Chemistry · 23
Conformationally Constrained Spiro C‐Arylglucosides as Potent and Selective Renal Sodium‐Dependent Glucose Co‐transporter 2 (SGLT2) Inhibitors
2010 · Binhua Lv, Yan Feng, et al. · ChemMedChem · 21
A novel anti-LAG-3/TIGIT bispecific antibody exhibits potent anti-tumor efficacy in mouse models as monotherapy or in combination with PD-1 antibody
2024 · Tongcheng Dai, Hao Sun, et al. · Scientific Reports · 19
Discovery of Potent SOS1 PROTACs with Effective Antitumor Activities against NCI-H358 Tumor Cells In Vitro/In Vivo
2024 · Xudong Pang, Dawei Cui, et al. · Journal of Medicinal Chemistry · 14
Study on Typical Diarylurea Drugs or Derivatives in Cocrystallizing with Strong H-Bond Acceptor DMSO
2021 · Chengwei Li, Jialiang Zhong, et al. · ACS Omega · 14
Evaluation of gecacitinib vs hydroxyurea in patients with intermediate-2 or high-risk myelofibrosis: final analysis results from a randomized phase 3 study
2024 · Yi Zhang, Hu Zhou, et al. · Blood Cancer Journal · 8
PDF
Design and Development of Potent SOS1 Inhibitors with Effective Antitumor Activities In Vitro/In Vivo
2025 · Xudong Pang, Dawei Cui, et al. · ACS Medicinal Chemistry Letters · 4
Abstract 6368: Preclinical pharmacology and safety studies of ZG005: an anti-PD-1/TIGIT bispecific mAb in a phase I clinical trial for advanced tumors
2023 · Bing Zhu, Tongcheng Dai, et al. · Cancer Research · 3
A randomized phase II dose optimization study for alveltamig (ZG006), a trispecific T-cell engager targeting DLL3/DLL3/CD3, as monotherapy in patients with refractory neuroendocrine carcinoma (ZG006-003).
2026 · Chuan Hua Zhao, Hanguang Hu, et al. · Journal of Clinical Oncology · 2
Intrahepatic targeting and sustained release of a Toll like receptor 8 agonist enhances hepatocellular carcinoma therapy
2025 · Zhongjie Tang, Tongcheng Dai, et al. · Journal of Controlled Release · 2
Absorption, metabolism, and excretion of oral [14C] radiolabeled donafenib: an open-label, phase I, single-dose study in humans
2024 · Sheng Ma, Ling Yi, et al. · Cancer Chemotherapy and Pharmacology · 2
Updated results of the phase 1 dose escalation and expansion study of alveltamig (ZG006), a trispecific T cell engager targeting DLL3/DLL3/CD3, as monotherapy in patients with refractory small cell lung cancer or neuroendocrine carcinoma.
2026 · Qiming Wang, Jianhua Shi, et al. · Journal of Clinical Oncology · 1
ZGGS15, a Novel IgG4 Bispecific Monoclonal Antibody Targeting Both LAG-3 and Tigit, Demonstrates Outstanding Anti-Tumor Activity and Can be Used As Monotherapy or in Combination with Anti-PD-1 Antibodies for Cancer Immunotherapy
2023 · Jifeng Yu, Tongcheng Dai, et al. · Blood · 1
Updated results of the randomized phase 2 dose optimization study of alveltamig (ZG006), a trispecific T cell engager targeting DLL3/DLL3/CD3, as monotherapy in patients with advanced small cell lung cancer.
2026 · Xinghao Ai, Yan Yu, et al. · Journal of Clinical Oncology
Nilvanstomig (ZG005), an anti-PD-1/TIGIT bispecific antibody, plus bevacizumab vs. sintilimab plus bevacizumab biosimilar as first-line therapy for advanced hepatocellular carcinoma: A randomized, multi-center, phase II trial.
2026 · Hong Wu, Lianxin Liu, et al. · Journal of Clinical Oncology
PDF
Exploring the therapeutic potential of deuterated PPARγ agonists for NASH
2025 · Xudong Pang, Dawei Cui, et al. · Bioorganic & Medicinal Chemistry Letters
Abstract 2790: Preclinical studies of ZG19018, a novel irreversible covalent inhibitor of KRAS G12C, for the treatment of advanced non-small cell lung cancer and other solid tumors
2023 · Bing Zhu, Dawei Cui, et al. · Cancer Research
Abstract 2323: ZGGS18, a bispecific drug candidate of anti-VEGF and TGFbeta-trap, inhibiting tumor proliferation and improving tumor microenvironment with I/O therapy
2023 · Ruifeng Liu, Alfonso Suarez, et al. · Cancer Research
Abstract 1618: A highly selective and potent TLR8 agonist ZG0895 in preclinical studies of anti-tumor activities
2023 · Dawei Cui, Ruifeng Liu, et al. · Cancer Research
Works count: 25
Citation count: 382
H-index: 11
I10-index: 11
Year
Topic
Type